Metastatic castration-resistant prostate cancer (mCRPC) represents a significant challenge in the oncology landscape, characterized by the progression of prostate cancer despite androgen deprivation therapy. With increasing awareness, advancements in treatment options, and evolving patient demographics, the market for mCRPC therapies is poised for substantial growth in the coming decade....
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian